

GW1929

Catalog No: tcsc1404



Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg



Specifications

CAS No:

196808-24-9

Formula:

$C_{30}H_{29}N_3O_4$

Pathway:

Cell Cycle/DNA Damage

Target:

PPAR

Purity / Grade:

>98%

Solubility:

DMSO : \geq 35 mg/mL (70.63 mM)

Observed Molecular Weight:

495.57

Product Description

GW1929 is a potent **PPAR- γ** activator, with pK_is of 8.84, PPAR- γ , PPAR- α , and PPAR- δ , and pEC₅₀s of 8.56 and 8.27 for human **PPAR- γ**


and murine **PPAR-γ**, respectively.

IC50 & Target: pKi: 8.84 (Human PPAR-γ), [1]

pEC50: 8.56 (Human PPAR-γ), 8.27 (Murine PPAR-γ)^[1]

In Vitro: GW1929 is a potent PPAR-γ activator, with pK_is of 8.84, 50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively^[1]. GW1929 (10 μM) inhibits TBBPA-induced caspase-3 increase and TBBPA-stimulated LDH release in neocortical cell cultures^[2].

In Vivo: GW1929 (0.5, 1, 5 mg/kg, p.o.) highly decreases nonfasted plasma glucose levels in Zucker diabetic fatty (ZDF) rats after treatment for 14 days, and possesses antilipolytic efficacy. GW1929 (1, 5 mg/kg, p.o.) increases glucose-stimulated insulin secretion of β-cell in ZDF rats^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!